Objective: To analyze the efficacy and safety of cytoreduction surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) in the early stage. Methods: The clinical data, including pathological features, recurrence and survival of 65 PMP patients in the early stage underwent CRS combined with HIPEC in Aerospace Center Hospital from January, 2011 to December, 2018 were retrospectively analyzed. Results: 65 patients with early stage PMP underwent CRS+ HIPEC. Among these patients, 25 were males and 40 were females, and the mean age was 52.5 years. The median peritoneal cancer index was 3 (0-16). The score of completeness of cytoreduction (CC) of 63 patients (96.9%) was 0, and 2 patients (3.1%) was 1. No perioperative death occurred, the incidence of surgical complications above grade 3 was 3.1%. Three patients relapsed during the follow-up period, including 1 patient with low-grade PMP, 1 patient with high-grade PMP, and 1 patient with high-grade PMP accompanied by signet ring cell. The 5-year disease-free survival rate of the whole group was 92.4%. Conclusions: PMP patients in the early stage treated by CRS combined with HIPEC can achieve benefit and safety. A close long-term follow-up is necessary.
目的： 评估肿瘤细胞减灭术(CRS)＋腹腔热灌注化疗(HIPEC)治疗早期阑尾源性腹膜假性黏液瘤(PMP)的安全性和疗效。 方法： 回顾性分析航天中心医院2011年1月至2018年12月采用CRS＋HIPEC治疗的65例PMP患者的临床资料，了解其临床特征、复发及生存情况。 结果： 65例早期PMP患者接受CRS＋HIPEC治疗，其中男25例，女40例；平均年龄52.5岁；中位腹膜癌指数为3分；肿瘤细胞减灭程度(CC)评分为0分者63例(96.9%)，1分者2例(3.1%)。全组无围手术期死亡患者，3级及以上手术并发症的发生率为3.1%。随访期内，3例患者复发，其中低级别PMP患者1例，高级别PMP患者1例，高级别PMP伴印戒细胞1例，全组患者的5年无复发生存率为92.4%。 结论： 对于临床早期PMP患者，CRS＋HIPEC治疗安全有效，术后长期密切的随访必不可少。.
Keywords: Cytoreductive surgery; Early stage; Hyperthermic intraperitoneal chemotherapy; Pseudomyxoma peritonei; Single center.